{
  "docId": "019de076-794e-71d3-9fbb-8ba3f121f554",
  "docSlug": "4ee48ed5e56c8ddc8f74aa05772c7ac4",
  "documentTitle": "Comera | Investor Presentation Deck | 16 slides",
  "authorId": "comera",
  "authorName": "Comera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 9,
  "pageCount": 16,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide highlights a 77% viscosity reduction for Infliximab and a 45-78% reduction for Ipilimumab.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-794e-71d3-9fbb-8ba3f121f554/9",
  "deckHref": "/decks/019de076-794e-71d3-9fbb-8ba3f121f554",
  "deckJsonHref": "/decks/019de076-794e-71d3-9fbb-8ba3f121f554.json",
  "deckAnchorHref": "/decks/019de076-794e-71d3-9fbb-8ba3f121f554#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.5,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Viscosity vs Ipilimumab concentration",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66e91b71-4d45-4bac-90e3-c60fe1e253bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Viscosity vs Infliximab concentration",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a64f2c53-89d4-462b-b95c-b8cf4d062857",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "paragraph",
      "text": "Infliximab formulated in a 20 mM phosphate-acetate buffer at pH 6.0 (control) and in the presence of 75 mM caffeine, 100 mM ArgHCl, or 100 mM NaCl",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93c57f62-a0e0-46ea-8fb7-11c857a59d59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.5,
        "y": 0.76
      },
      "kind": "paragraph",
      "text": "Ipilimumab formulated in Yervoy commercial formulation vehicle (Comm.) and PBS with or without 75 mM caffeine",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5db011e-63bd-462c-9a1e-5421c9b5dfa4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.05,
        "y": 0.84
      },
      "kind": "source-note",
      "text": "Source: “Caffeine as a viscosity reducer for highly concentrated monoclonal antibody solutions” Journal of Pharmaceutical Sciences 110 (2021) 3594–3604",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "858d5cb3-dead-49a9-90d8-a767fd521b91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.048,
        "y": 0.16
      },
      "kind": "title",
      "text": "SQore Platform Optimized to Lower Viscosity for Several Biologics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fe75bf9-085b-44ac-96a7-1c4e77dec999",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "b30169c7-3829-47f0-addf-ee3c13e9281e",
      "evidence": "The slide presents multiple charts for data visualization.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 6,
      "beatId": "f192b7d0-87c2-4c37-b6d9-2dc7cad32dc8",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The deck provides evidence and proof of the SQore platform's effectiveness.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "d0fe045e-0c5c-47f4-bb13-8b12e4725574",
      "evidence": "The deck presents the SQore platform and its advantages, using the golden circle framework.",
      "position": 1,
      "objective": "Why is Comera's SQore platform a compelling solution?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}